Cancer Risk in Diabetic Patients Treated with Metformin: A Systematic Review and Meta-analysis
Open accessThe DOI matches its Crossref record; 105 of the 106 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A growing body of evidence has suggested that metformin potentially reduces the risk of cancer. Our objective was to enhance the precision of estimates of the effect of metformin on the risk of any-site and site-specific cancers in patients with diabetes. METHODS/PRINCIPAL FINDINGS: We performed a search of MEDLINE, EMBASE, ISI Web of Science, Cochrane Library, and ClinicalTrials.gov for pertinent articles published as of October 12, 2011, and included them in a systematic review and meta-analysis. We calculated pooled risk ratios (RRs) for overall cancer mortality and cancer incidence. Of the 21,195 diabetic patients reported in 6 studies (4 cohort studies, 2 RCTs), 991 (4.5%) cases of death from cancer were reported. A total of 11,117 (5.3%) cases of incident cancer at any site were reported among 210,892 patients in 10 studies (2 RCTs, 6 cohort studies, 2 case-control studies). The risks of cancer among metformin users were significantly lower than those among non-metformin users: the pooled RRs (95% confidence interval) were 0.66 (0.49-0.88) for cancer mortality, 0.67 (0.53-0.85) for all-cancer incidence, 0.68 (0.53-0.88) for colorectal cancer (n = 6), 0.20 (0.07-0.59) for hepatocellular cancer (n = 4), 0.67 (0.45-0.99) for lung cancer (n = 3). CONCLUSION/SIGNIFICANCE: The use of metformin in diabetic patients was associated with significantly lower risks of cancer mortality and incidence. However, this analysis is mainly based on observational studies and our findings underscore the more need for long-term RCTs to confirm this potential benefit for individuals with diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Metformin may also confer a decreased cancer risk in patients with diabetes (90).”
From Cellular Senescence in Type 2 Diabetes: A Therapeutic Opportunity (2015) · cites this paper as [90]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164 · cited 1×
“All the procedures were in accordance with the guidelines for the Quality of Reporting of Meta-analyses [24], the meta-analysis of observational studies in epidemiology [25] and the PRISMA statement [26].”
MethodDermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040296 · Cited by 23,020
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.11.008 · Cited by 17,893
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-8-200710160-00010 · Cited by 17,796
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-18 · Cited by 13,371
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00136 · Cited by 10,349
Lopez, A. D., Mathers, C. D., Ezzati, M., Jamison, D. T., & Murray, C. J. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68770-9 · Cited by 5,630 · cited 1×
“In light of the fact that cancer is the second and diabetes the twelfth leading cause of death worldwide [59] and that the number of people with diabetes is”
Background
Cited by
Items 301–400 of 580
Chun, S. G., Liao, Z. X., Jeter, M. D., Chang, J. Y., Lin, S. H., Komaki, R. U., Guerrero, T. M., Mayo, R. C., Korah, B. M., Koshy, S. M., et al. (2020) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000632 · Cited by 22
“RECIST SD: 14 (100) PR: 3 (23) SD: 3 (23) SMD: 6 (43) CMR: 9 (69) PERCIST PMD: 6 (43) PMD: 1 (8) PMR: 2 (14) PMR: 3 (23)”
Management of colorectal cancer and diabetes
Yao, C., Nash, G. F., & Hickish, T. (2013) · Journal of the Royal Society of Medicine · doi:10.1177/0141076813512121 · Cited by 23
“There are currently few randomised controlled trials to support this hypothesis and in practice this would be difficult to carry out.(19,20) Alteration in bowel habit in diabetic patients is common due to both medications and the disease process.”
BackgroundNo association between metformin use and survival in patients with pancreatic cancer
Frouws, M. A., Mulder, B. G. S., Bastiaannet, E., Zanders, M. M. J., van Herk‐Sukel, M. P. P., de Leede, E. M., Bonsing, B. A., Mieog, J. S. D., van de Velde, C. J. �., & Liefers, G. (2017) · Medicine · doi:10.1097/md.0000000000006229 · Cited by 22
“The decision to prescribe metformin depends on patient characteristics; metformin use is contraindicated in patients with renal failure, cardiac dysfunction, and hepatic insufficiency.”
BackgroundRen, D., Qin, G., Zhao, J., Sun, Y., Zhang, B., Li, D., Wang, B., Jin, X., & Wu, H. (2020) · PubMed · Cited by 34
Alsheikh, H. A., Metge, B. J., Ha, C., Hinshaw, D. C., Mota, M., Kammerud, S. C., Lama-Sherpa, T. D., Sharafeldin, N., Wende, A. R., Samant, R. S., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.05.022 · Cited by 21
Taira, A. V., Merrick, G. S., Galbreath, R. W., Morris, M., Butler, W. M., & Adamovich, E. (2014) · Journal of Contemporary Brachytherapy · doi:10.5114/jcb.2014.45757 · Cited by 21
Nie, S., Chen, H., Zhuang, M., & Lü, M. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.16.6863 · Cited by 21
Impact of Diabetes on Outcomes of Sorafenib Therapy for Hepatocellular Carcinoma
Costanzo, G. G. D., Tortora, R., Morisco, F., Addario, L., Guarino, M., Cordone, G., Falco, L., & Caporaso, N. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0454-5 · Cited by 23
Metformin to Treat Cancer: Misstep in Translational Research from Observational Studies
Suissa, S. (2017) · Epidemiology · doi:10.1097/ede.0000000000000634 · Cited by 22
Cancer Prevention: Lessons Learned and Future Directions
Dunn, B. K., & Kramer, B. S. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.11.003 · Cited by 21
Saito, A., Koinuma, K., Kawashima, R., Miyato, H., Ohzawa, H., Horie, H., Yamaguchi, H., Kawahira, H., Mimura, T., Kitayama, J., et al. (2023) · BJC Reports · doi:10.1038/s44276-023-00022-w · Cited by 20
Diabetes Mellitus as a Novel Risk Factor for Gastrointestinal Malignancies
Herrigel, D. J., & Moss, R. A. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.10.2825 · Cited by 24
Wang, F., Xu, J., LIU, H., Liu, Z., & XIA, F. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5143 · Cited by 20
“For example, retrospective studies in patients with type 2 diabetes showed reduced cancer incidence in patients who had been treated with metformin for several years (8-11).”
Wang, F., Ding, X., Wang, T., Shan, Z., Wang, J., Wu, S., Chi, Y., Zhang, Y., Lv, Z., Wang, L., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174276 · Cited by 21
Targeting Oxygen-Sensing Prolyl Hydroxylase for Metformin-Associated Lactic Acidosis Treatment
Oyaizu-Toramaru, T., Suhara, T., Hayakawa, N., Nakamura, T., Kubo, A., Minamishima, S., Yamaguchi, K., Hishiki, T., Morisaki, H., Suematsu, M., et al. (2017) · Molecular and Cellular Biology · doi:10.1128/mcb.00248-17 · Cited by 21
Metformin Is Associated With Reduced Odds for Colorectal Cancer Among Persons With Diabetes
Demb, J., Yaseyyedi, A., Liu, L., Bustamante, R., Earles, A., Ghosh, P., Gutkind, J. S., Gawron, A. J., Kaltenbach, T. R., Martínez, M. E., et al. (2019) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000092 · Cited by 20
Zhan, Z., Liu, L., Cheng, M., Gao, Y., & Zhou, W. (2022) · Journal of Immunology Research · doi:10.1155/2022/2651790 · Cited by 25
“Previous large case-control studies revealed that metformin treatment reduced the incidence of various cancer types [13, 48, 49].”
BackgroundChen, S., Hsueh, C., Chiou, W., & Lin, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055179 · Cited by 20
“Theoretically, diabetes treatments involving insulin or metformin may increase or decrease hyperinsulinemia, and these changes may influence the incidence or treatment results in different cancers [23,24].”
BackgroundSynergistic drug combinations from electronic health records and gene expression
Low, Y., Daugherty, A. C., Schroeder, E. A., Chen, W., Seto, T., Weber, S., Lim, M., Hastie, T. J., Mathur, M. B., Desai, M., et al. (2016) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocw161 · Cited by 22
Eser, N., YOLDAŞ, A., Türk, A., Yiğin, A. K., Yalçın, A., & Çiçek, M. (2021) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgab023 · Cited by 19
Mesquita, L. A., Spiazzi, B. F., Piccoli, G. F., Nogara, D. A., da Natividade, G. R., Garbin, H. I., Wayerbacher, L. F., Wiercinski, V. M., Baggio, V. A., Zingano, C. P., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15509 · Cited by 20
“The search strategy consisted of terms for the intervention (metformin and relevant synonyms) and a filter for RCTs specific for each database, except for CENTRAL, which is focused on RCTs (Table S2).”
MethodResultInfluentialFaillie, J., & Suissa, S. (2014) · Therapies · doi:10.2515/therapie/2014207 · Cited by 22
“Des métaanalyses d’études observationnelles ont rapporté une réduction significative de plus de 30 % du risque de cancer associé à l’utilisation de la metformine chez des sujets diabétiques.[11,12] Parmi ces études, nombreuses étaient celles qui souffraient, à des degrés divers, d’un biais de temps immortel.”
Backgroundde Heer, J., & Göke, B. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.955013 · Cited by 21
“Accordingly, several studies described a reduced overall cancer risk and mortality in diabetic patients treated with metformin and PPAR-g agonists [40-42] and a higher risk for those treated Incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas”
BackgroundShen, T., Chung, W., Lin, C., Wei, C., Chen, C., Chen, H.-J., Tu, C., Hsia, T., Shih, C., Hsu, W., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098290 · Cited by 19
“reported a systemic review and meta-analyses that the use of metformin in diabetic patients was associated with significantly lower risks of cancer mortality and incidence [34].”
BackgroundMetformin upregulates E-cadherin and inhibits B16F10 cell motility, invasion and migration
Liang, G., DING, M., Lu, H., CAO, N., Niu, Y.-D., Gao, Y., & Lu, J. (2015) · Oncology Letters · doi:10.3892/ol.2015.3475 · Cited by 25
“A retrospective epidemiological study demonstrated a reduction in cancer risk in diabetic patients treated with metformin (13).”
RetractedThyroid Cancer Metabolism: A Review
Gill, K. S., Tassone, P. T., Hamilton, J., Hjelm, N., Luginbuhl, A., Cognetti, D. M., Tuluc, M., Martinez‐Outschoorn, U., Johnson, J. M., & Curry, J. (2016) · Journal of Thyroid Disorders & Therapy · doi:10.4172/2167-7948.1000200 · Cited by 23
“Epidemiologic studies have also shown a decreased risk of cancer incidence and mortality from metformin use in diabetics [72], and clinical trials elucidating metformin’s effect on head and neck squamous cell carcinoma are already underway.”
BackgroundAsarone and metformin delays experimentally induced hepatocellular carcinoma in diabetic milieu
Das, B. K., Choukimath, S. M., & Gadad, P. C. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.05.046 · Cited by 19
Something old, something new and something very old: drugs for treating type 2 diabetes
Kaiser, D., & Oetjen, E. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12624 · Cited by 24
“In the case of metformin, the beneficial effects clearly outweigh its potential risks: metformin was shown to prevent cardiovascular mortality and disease (UKPDS 34, 1998) and might reduce cancer incidence (Evans et al., 2005; Libby et al., 2009; Noto et al., 2012; van Staa et al., 2012).”
BackgroundMolecular action and pharmacogenetics of metformin: current understanding of an old drug
Rena, G., Pearson, E. R., & Sakamoto, K. (2012) · Diabetes Management · doi:10.2217/dmt.12.42 · Cited by 22
Metformin and breast cancer: Basic knowledge in clinical context
Pizzuti, L., Vici, P., Lauro, L. D., Sergi, D., Giulia, M. D., Marchetti, P., Maugeri‐Saccà, M., Giordano, A., & Barba, M. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.03.002 · Cited by 18
“Data from observational studies focusing on diabetic patients have shown significantly decreased risk of breast cancer development and better cancer-related treatment outcomes in women taking metformin because of metabolic disturbances [5,6].”
BackgroundGlargine safety, diabetes and cancer
Rendell, M., Aktürk, H. K., & Tella, S. H. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.770469 · Cited by 19
“Overall cancer mortality is lower in metformin-treated patients (Table 6) [109-115].”
BackgroundDuan, W., Qian, W., Zhou, C., Cao, J., Qin, T., Xiao, Y., Cheng, L., Li, J., Chen, K., Li, X., et al. (2018) · Oncology Reports · doi:10.3892/or.2018.6518 · Cited by 23
Kim, Y.-S., Choi, E.-A., Lee, J., Kim, Y., You, H., Han, Y.-E., Kim, H.-S., Bae, Y., Kang, H., & Kim, J. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.05.010 · Cited by 19
Yip, K., Tsai, T., Yang, I., Miao, Z., Chen, Y., Li, C., Su, W., Chang, T., Huang, C., Tsai, H., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10050955 · Cited by 20
Metformin for treatment of cytopenias in children and young adults with Fanconi anemia
Pollard, J. A., Furutani, E., Liu, S., Esrick, E. B., Cohen, L. E., Bledsoe, J. R., Liu, C., Lü, K., Ramírez, M. J., Surrallés, J., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006490 · Cited by 22
“Platelets (cells/mL) 14 53,800 cells/mL (16-78) 11,500 cells/mL (0-49) 31.”
Screening of GPCR drugs for repurposing in breast cancer
Abdulkareem, N. M., Bhat, R. R., Powell, R. T., Chikermane, S. G., Yande, S., Trinh, L., Abdelnasser, H. Y., Tabassum, M., Ruiz, A., Sobieski, M. M., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1049640 · Cited by 22
“For example, metformin used to treat diabetes, is found to have anti-cancer effects and may also prevent tumor development, possibly by inhibiting the AMPK/mTOR pathway and immunomodulation (Bodmer et al., 2010; Noto et al., 2012; Franciosi et al., 2013; Wu et al., 2015; Chae et al., 2016; Gong et al., 2016; Higurashi…”
BackgroundBerstein, L. M., Iyevleva, A. G., Vasilyev, D., Евгеньевна, П. Т., & Имянитов, Е. Н. (2013) · Cell Cycle · doi:10.4161/cc.26868 · Cited by 22
“DM, all (96) 46,5 ± 5,4 (85)1 81,8 ± 11,5 (11) 51,8 ± 5,4 (82) 42,8 ± 13,2 (14) 39,1 ± 10,2 (22) 54,1 ± 5,9 (74)”
InfluentialAnti-tumour effect of metformin in canine mammary gland tumour cells
Saeki, K., Watanabe, M., Tsuboi, M., Sugano, S., Yoshitake, R., Tanaka, Y., Ong, S. M., Saito, T., Matsumoto, K., Fujita, N., et al. (2015) · The Veterinary Journal · doi:10.1016/j.tvjl.2015.04.026 · Cited by 20
Pasanisi, P., Gargano, G., Mauro, M. G. D., Cortellini, M., Casagrande, A., Villarini, A., Bruno, E., Roveda, E., Saibene, G., Venturelli, E., et al. (2017) · Tumori Journal · doi:10.5301/tj.5000599 · Cited by 19
Lee, D. J., McMullen, C. P., Foreman, A., Huang, S. H., Lu, L., Xu, W., de Almeida, J. R., Liu, G., Bratman, S. V., & Goldstein, D. P. (2019) · Journal of Otolaryngology - Head and Neck Surgery · doi:10.1186/s40463-019-0348-5 · Cited by 17
Association Between Diabetes and the Risk of Kidney Cancer: Systematic Review and Meta-Analysis
Bonilla-Sanchez, A., Rojas-Munoz, J., & García‐Perdomo, H. A. (2022) · Clinical Diabetes · doi:10.2337/cd21-0013 · Cited by 17
Júnior, A. D. D. C., Zanette, D. L., Pericole, F. V., Saad, S. T. O., & Carvalheira, J. B. C. (2021) · Advances in Hematology · doi:10.1155/2021/6615684 · Cited by 20
Metformin combined with local irradiation provokes abscopal effects in a murine rectal cancer model
Tojo, M., Miyato, H., Koinuma, K., Horie, H., Tsukui, H., Kimura, Y., Kaneko, Y., Ohzawa, H., Yamaguchi, H., Yoshimura, K., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-11236-2 · Cited by 19
Du, Y., Zheng, H., WANG, J., Ren, Y., Li, M., Chen, G., Xu, F., & Yang, C. (2014) · Oncology Letters · doi:10.3892/ol.2014.2158 · Cited by 17
Zhou, C., Ren, Y. T., Li, J., Wang, K., He, J., Chen, W., & Liu, P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095699 · Cited by 18
“In the metaanalysis of the eight studies, the individual and pooled estimates comparing the preventive effects of different irrigation fluid types and volumes were not neutral [58].”
BackgroundDevelopment and validation of a Health Policy Model of Type 2 diabetes in Chinese setting
Wu, B. Y., Ma, J., Zhang, S., Zhou, L., & Wu, J. (2018) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2018-0001 · Cited by 18
Statin Use and Cancer Incidence in Patients with Type 2 Diabetes Mellitus: A Network Meta-Analysis
Hu, Y., Hu, E.-D., & Fu, R. (2018) · Gastroenterology Research and Practice · doi:10.1155/2018/8620682 · Cited by 17
“When patients were treated with metformin, their risk of cancer may be reduced [47, 48].”
BackgroundMetformin Induces Apoptosis and Inhibits Notch1 in Malignant Pleural Mesothelioma Cells
Rossini, M., Martini, F., Torreggiani, E., Fortini, F., Aquila, G., Sega, F. V. D., Patergnani, S., Pinton, P., Maniscalco, P., Cavallesco, G., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.534499 · Cited by 16
Keys, M. T., Thinggaard, M., Larsen, L. A., Pedersen, D. A., Hallas, J., & Christensen, K. (2022) · International Journal of Epidemiology · doi:10.1093/ije/dyac200 · Cited by 16
Metformin and Cancer in Type 2 Diabetes
Park, H. K. (2013) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2013.37.2.113 · Cited by 17
“org exposure durations, epidemiologic studies have demonstrated that insulin secretagogues and insulin use may increase the cancer risk, while metformin is associated with a lower risk of cancer [13-18].”
BackgroundMetformin and cancer: Technical and clinical implications for FDG-PET imaging
Capitanio, S., Marini, C., Sambuceti, G., & Morbelli, S. D. (2015) · World Journal of Radiology · doi:10.4329/wjr.v7.i3.57 · Cited by 16
Gu, Y., Hou, X., Zheng, Y., Wang, C., Zhang, L., Li, J., Huang, Z., Han, M., Bao, Y., Zhong, W., et al. (2016) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph13060559 · Cited by 17
“Results of a growing number of studies suggested that treatment with metformin was associated with reduced risk and mortality of cancer [15,16].”
BackgroundTian, S., Lei, H., Liu, Y., Chen, Y., & Dong, W. (2017) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2017.06.001 · Cited by 16
Hui, T., Shang, C., Liu, Y., Wang, M., Li, R., & Song, Z. (2021) · Scientific Reports · doi:10.1038/s41598-021-89475-y · Cited by 16
AMP-activated protein kinase regulates hERG potassium channel
Almilaji, A., Muñoz, C., Elvira, B., Fajol, A., Pakladok, T., Honisch, S., Shumilina, E. V., Lang, F. J. W., & Föller, M. (2013) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-013-1299-8 · Cited by 16
“Accordingly, pharmacological activation of AMPK is considered a successful strategy against cancer, and growing evidence suggests that the widely used drug and AMPK activator metformin exerts anti-tumor effects [28, 33].”
BackgroundKoo, H. Y., Jeong, S., Cho, M. H., Chun, S., Shin, D. W., & Park, J. (2021) · Scientific Reports · doi:10.1038/s41598-021-95764-3 · Cited by 15
Khader, E., Ismail, W., Mhaidat, N. M., & Alqudah, M. A. Y. (2021) · PubMed Central · Cited by 23
Impact of diabetes on the increased risk of hepatic cancer: An updated review of biological aspects
Das, B. K., & Gadad, P. C. (2021) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2021.100025 · Cited by 16
Kim, D., Ahn, B., Kim, Y. S., Hur, D. Y., Yang, J. W., Park, G. B., Jang, J. E., Lee, E. J., Kwon, M. J., Kim, T. N., et al. (2019) · Journal of Diabetes Research · doi:10.1155/2019/2376512 · Cited by 15
Ghiasi, B., Sarokhani, D., Najafi, F., Motedayen, M., & Dehkordi, A. H. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190215123759 · Cited by 17
Manna, E. D. F., Serrano, D., Aurilio, G., Bonanni, B., & Lazzeroni, M. (2023) · Healthcare · doi:10.3390/healthcare11162360 · Cited by 19
Lyall, M. J., Thethy, I., Steven, L., Mackean, M., Nussey, F., Sakala, M., Rye, T., Strachan, M. W. J., & Dover, A. R. (2018) · Diabetic Medicine · doi:10.1111/dme.13770 · Cited by 19
Metformin and the risk of renal cell carcinoma: a case–control analysis
Becker, C., Jick, S. S., Meier, C. R., & Bodmer, M. (2016) · European Journal of Cancer Prevention · doi:10.1097/cej.0000000000000246 · Cited by 14
Calorie restriction mimetics against aging and inflammation
Chaudhary, S., Chaudhary, M. R., Jena, M. K., Rath, P. K., Mishra, B. P., Paital, B., Vyas, A., Sahoo, D. K., Singh, P., & Mehdi, M. M. (2025) · Biogerontology · doi:10.1007/s10522-025-10269-0 · Cited by 15
Sahu, P., Camarillo, I. G., & Sundararajan, R. (2021) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-021-03723-5 · Cited by 13
“For instance, a population-based observational study shows an association between the reduced risk of various cancers in patients with type 2 diabetes and metformin usage [1, 2].”
BackgroundMicallef, D. A., Micallef, S., Schembri-Wismayer, P., & Calleja‐Agius, J. (2016) · Journal of the Turkish-German Gynecological Association · doi:10.5152/jtgga.2016.15200 · Cited by 13
Sekino, N., Kano, M., Kobayashi, S., Murakami, K., Sakata, H., Toyozumi, T., Endo, S., Matsumoto, Y., Suito, H., Takahashi, M., et al. (2022) · Oncology · doi:10.1159/000522446 · Cited by 11
GLP-1 receptor agonist as treatment for cancer as well as diabetes: beyond blood glucose control
Nomiyama, T., & Yanase, T. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2016.1191349 · Cited by 14
“describe the anticancer effects, particularly in liver cancer, of antidiabetic agents such as metformin [27] and thiazolidine-”
BackgroundWu, H., Walker, J. J., Damhuis, R. A. M., Brewster, D., & Wild, S. H. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.07.020 · Cited by 13
Wang, G., Li, X., Xiong, R., Wu, H., Xu, M., & Xie, M. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13398 · Cited by 12
Gifford, G. K., Gifford, A. J., Chen, Q., Shen, Y., Gabrielli, S., Gill, A. J., Stevenson, W. S., & Best, G. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1742899 · Cited by 12
Metformin for lung cancer prevention and improved survival: a novel approach
Roos, J. F., Qudsi, M., Samara, A., Rahim, M. M., Al-Bayedh, S. A., & Ahmed, H. (2018) · European Journal of Cancer Prevention · doi:10.1097/cej.0000000000000442 · Cited by 11
“Increasing evidence from observational studies and metaanalyses suggests that metformin is associated with reduction in both cancer risk (Evans et al., 2005; Noto et al., 2012) and cancer mortality (Bowker et al.”
BackgroundAssociation of the metformin with the risk of lung cancer: a meta-analysis.
Wang, L., Song, Y., Wu, G., & Yuan, D. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2013.08.01 · Cited by 11
“A meta-analysis has demonstrated that metformin associated with reduced mortality and incidence of cancer in patients with DM (9).”
BackgroundYang, B., Huang, C., Yu, T., Zhou, S., Liu, Q., Liu, G.-J., Chen, S., & Han, F. (2017) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000483 · Cited by 11
Insulin-IGF signaling affects cell transformation in the BALB/c 3T3 cell model
Poburski, D., Leovsky, C., Boerner, J. B., Szimmtenings, L., Ristow, M., Glei, M., & Thierbach, R. (2016) · Scientific Reports · doi:10.1038/srep37120 · Cited by 10
Panahandeh, P., Bertelsen, B.-E., Viste, K., Chatziioannou, A. C., Bellerba, F., Robinot, N. R., Trolat, A., Flågeng, M. H., Scalbert, A., Keski‐Rahkonen, P., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-01705-9 · Cited by 10
“Treatment with metformin, in contrast to other anti-diabetic drugs such as insulin and sulfonylurea, lowers the risk of cancer-associated mortality 17,19,20 .”
Will metformin use lead to a decreased risk of thyroid cancer? A systematic review and meta-analyses
Li, H., Chen, Y., Hu, L., Yang, W., Gao, Z., Liu, M., Tao, H., & Li, J. (2023) · European Journal of Medical Research · doi:10.1186/s40001-023-01287-0 · Cited by 10
Liou, W., Chen, L.-J., Niu, H., Yang, T., Cheng, J., & Lin, K. (2014) · Journal of Applied Biomedicine · doi:10.1016/j.jab.2014.11.001 · Cited by 11
“The administration of metformin to diabetic patientswas associatedwith lower risks of cancer incidence andmortality (Noto et al., 2012).”
BackgroundRepurposing existing agents as adjunct therapies for glioblastoma
Purow, B. W. (2015) · Neuro-Oncology Practice · doi:10.1093/nop/npv041 · Cited by 10
Philippou, E. (2016) · CRC Press eBooks · doi:10.1201/9781315371764 · Cited by 12
Kuno, T., Hata, K., Takamatsu, M., Hara, A., Hirose, Y., Takahashi, S., Imaida, K., & Tanaka, T. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15059160 · Cited by 9
“Furthermore, metformin is associated with a lower risks of colorectal cancer, hepatocellular cancer, and lung cancer [10], and thus the chemopreventive and therapeutic potential of metformin in non-small cell lung cancer is currently being evaluated in several clinical trials, some of which have advanced to Phase III…”
BackgroundWelponer, T., Weber, D. D., Trattner, L., Tockner, B., Aminzadeh-Gohari, S., Leb‐Reichl, V., Kaufmann, A., Zauner, R., Wimmer, M., Wally, V., et al. (2023) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.19488 · Cited by 10
Wilkie, M. D., Anaam, E. A., Lau, A., Rubbi, C. P., Vlatković, N., Jones, T. M., & Boyd, M. T. (2021) · Cancers · doi:10.3390/cancers13194836 · Cited by 9
“re-purposing metformin as a therapeutic agent in the context of cancer treatment [51], an interest which stems from several epidemiological studies demonstrating a lower cancer incidence in diabetic patients taking metformin than in the general diabetic population [52], and retrospective data indicating that metformin…”
BackgroundZhu, M., Wang, J., & Zhou, R. (2022) · Acta Biochimica Polonica · doi:10.18388/abp.2020_5750 · Cited by 11
“It has been found that metformin improved survival among diabetic patients with head and neck cancer (Franciosi et al., 2013; Noto et al., 2012).”
BackgroundTaylor, S. E., Chan, D., Yang, D., Bruno, T., Lieberman, R. W., Siddiqui, J., Soong, T. R., Coffman, L. G., & Buckanovich, R. J. (2022) · Cancers · doi:10.3390/cancers14092298 · Cited by 9
Salehi, A., Wang, L., Gu, X., Coates, P. J., Spaak, L. N., Sgaramella, N., & Nylander, K. (2024) · Oncology Letters · doi:10.3892/ol.2024.14275 · Cited by 8
“Metformin users may also have a reduced risk of acquiring cancers such as colorectal, liver, lung, prostate and breast (23), although recent data suggest that this issue is contro‑ versial and remains to be proven (24).”
BackgroundWong, C. S., Chu, W., Ashamalla, S., Fenech, D. S., Berry, S. R., Kiss, A., & Koritzinsky, M. (2021) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2021.07.001 · Cited by 9
Dhawan, A., Pifer, P. M., Sandulache, V. C., & Skinner, H. D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1016217 · Cited by 8
Kim, N. E., Kang, E.-H., Ha, E., Lee, J., & Lee, J. H. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1118863 · Cited by 8
“Although many studies have reported that metformin, one of the most widely prescribed anti-diabetic drugs, reduces the risk of cancer (30, 31), a large observational study in the United Kingdom showed that metformin use was not associated with a decreased risk of lung cancer (32).”
BackgroundCancer biology in diabetes update: Focusing on antidiabetic drugs
Kawakita, E., & Kanasaki, K. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14152 · Cited by 8
“Several epidemiological data have identi fi ed the link between metformin use and the risk reduction in cancer incidence and mortality of patients with diabetes 70 – 74 .”
BackgroundBosco, C., Wulaningsih, W., Melvin, J. C., Santaolalla, A., Piano, M. D., Arthur, R., & Hemelrijck, M. V. (2015) · ecancermedicalscience · doi:10.3332/ecancer.2015.555 · Cited by 8
Biomarkers of cancer angioprevention for clinical studies
Albini, A., Bertolini, F., Bassani, B., Bruno, A., Gallo, C., Caraffi, S. G., Maramotti, S., & Noonan, D. M. (2015) · ecancermedicalscience · doi:10.3332/ecancer.2015.600 · Cited by 8
Peng, J., Jing, X., Wu, J., Hong, D., Hu, X., Wang, Q., Hu, H., & Cai, X. (2020) · BioMed Research International · doi:10.1155/2020/1068671 · Cited by 10
Roque, D. R., Zhang, L., Wysham, W. Z., Han, J., Sun, W., Yin, Y., Livingston, J. N., Batchelor, K. W., Zhou, C., & Bae-Jump, V. L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.690435 · Cited by 8
The effect and mechanism of action of metformin on in vitro FaDu cell proliferation
Sun, R., Ma, X., Cai, X., Pan, X., & Liu, D. (2016) · Journal of International Medical Research · doi:10.1177/0300060516642645 · Cited by 9
Therapeutic potential of the antidiabetic drug metformin in small bowel adenocarcinoma
Chiyo, T., Kato, K., Iwama, H., Fujihara, S., Fujita, K., Tadokoro, T., Oura, K., Samukawa, E., Yamana, Y., Kobayashi, N., et al. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.3971 · Cited by 8
Quimby, A. E., Lebo, N. L., Griffiths, R., Hall, S. F., Dimitroulakos, J., & Johnson‐Obaseki, S. (2018) · Journal of Otolaryngology - Head and Neck Surgery · doi:10.1186/s40463-018-0322-7 · Cited by 8
Hong, J., Maacha, S., Pidkovka, N. A., Bates, A. L., Salaria, S. N., Washington, M. K., & Belkhiri, A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.903874 · Cited by 7
“Notably, retrospective epidemiological studies showed that diabetes patients have decreased cancer incidence with metformin (32, 33).”
BackgroundVelliquette, R. A., Rajgopal, A., Rebhun, J. F., & Glynn, K. M. (2017) · Obesity · doi:10.1002/oby.22061 · Cited by 7
“Meta-analyses of metformin on cardiovascular and cancer risks have shown this naturally derived diabetic drug and AMPK activator significantly reduces these risks in populations with diabetes (33,34).”
BackgroundMetformin use associated with lower risk of cancer in patients with diabetes mellitus type 2
Kusturica, J., Kulo, A., Gušić, E., Kapo, S. M., Rakanović-Todić, M., & Šečić, D. (2017) · Medicinski Glasnik · doi:10.17392/910-17 · Cited by 8
“However, the results of preclinical and clinical studies of antineoplastic activity of metformin are contradictory (17-20).”
Background
Metadata
- Authors
- Noto, H., Goto, A., Tsujimoto, T., & Noda, M.
- Affiliations
- National Center for Global Health and Medicine (JP)
- Corresponding author
- Noto, Hiroshi
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-03-20
- Volume
- 7
- Issue
- 3
- Pages
- e33411
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3308971
- OpenAlex
- W2040608814
- Cited by
- 566
- References
- 106
- Citations by year
- 2026: 16 · 2025: 15 · 2024: 20 · 2023: 29 · 2022: 28 · 2021: 33 · 2020: 41 · 2019: 38 · 2018: 28 · 2017: 50 · 2016: 60 · 2015: 57 · 2014: 60 · 2013: 65 · 2012: 25
- FWCI
- 6.04
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Ministry of Health, Labour and Welfare
- Japan Diabetes Foundation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Oncology › Cancer Risks and Factors
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- metformin, diabetes mellitus, cancer risk, cancer mortality, cancer incidence, colorectal cancer, hepatocellular carcinoma, lung cancer, chemoprevention
- MeSH terms
- Clinical Trials as Topic, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Metformin, Neoplasms, Risk Factors, Meta-Analysis as Topic, Incidence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.